KDR and breast carcinoma: Ebrahimi et colleagues developed a second generation of citric dendrimer (dendrimer-G2) combined with a VEGF antagonist for imaging and therapeutic purposes in breast cancer exploiting the VEGFR overexpression in this malignancy [25].